Uncategorized

Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

Published

on

While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version